Provectus Biopharmaceuticals Stock Shares Owned By Institutions
| PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Provectus Biopharmaceuticals fundamentals help investors to digest information that contributes to Provectus Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Provectus OTC Stock. The fundamental analysis module provides a way to measure Provectus Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Provectus Biopharmaceutica otc stock.
Provectus |
Provectus Biopharmaceuticals OTC Stock Shares Owned By Institutions Analysis
Provectus Biopharmaceutica's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Provectus Biopharmaceutica Shares Owned By Institutions | 0.04 % |
Most of Provectus Biopharmaceutica's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Provectus Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
CompetitionBased on the latest financial disclosure, 0.04% of Provectus Biopharmaceuticals are shares owned by institutions. This is 99.91% lower than that of the Pharmaceuticals sector and 99.92% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 99.9% higher than that of the company.
Provectus Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Provectus Biopharmaceutica's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Provectus Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Provectus Biopharmaceutica by comparing valuation metrics of similar companies.Provectus Biopharmaceutica is currently under evaluation in shares owned by institutions category among its peers.
Provectus Fundamentals
| Return On Asset | -1.85 | ||||
| Operating Margin | (4.77) % | ||||
| Current Valuation | 46.73 M | ||||
| Shares Outstanding | 419.55 M | ||||
| Shares Owned By Insiders | 3.69 % | ||||
| Shares Owned By Institutions | 0.04 % | ||||
| Number Of Shares Shorted | 1.82 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 5.44 X | ||||
| Price To Sales | 55.94 X | ||||
| EBITDA | (4.56 M) | ||||
| Net Income | (5.54 M) | ||||
| Cash And Equivalents | 84.27 K | ||||
| Total Debt | 2.29 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 0.27 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (1.01 M) | ||||
| Short Ratio | 0.47 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 3.5 | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 44.47 M | ||||
| Total Asset | 3.51 M | ||||
| Retained Earnings | (180.8 M) | ||||
| Working Capital | 10.6 M | ||||
| Current Asset | 14.72 M | ||||
| Current Liabilities | 4.12 M | ||||
| Z Score | -59.7 | ||||
| Net Asset | 3.51 M |
About Provectus Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Provectus Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Provectus Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Provectus Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |